Andrew J Sun, MD
Urology · Honolulu
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Aloha Urology Inc · 5 clinicians in this group
Looking this up.
Hospitals listed: The Queens Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Sun’s office at (808) 599-7779 to ask if they take your plan before you enroll.
California Medical Board record
Licence A137673 · Current
Licensed to practise in California · since 2015 · expires 2026-10-31 · University of Southern California Keck School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- The Queens Medical CenterHonolulu, HIAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of The Queens Health Systems, which runs 4 hospitalsPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.34 (1.12 to 1.55), Jul 2022 – Jun 2024Worse than the national rate — Iatrogenic pneumothorax rate: 0.47 (0.29 to 0.65) · 11,638 cases, Jul 2022 – Jun 2024Worse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.32 (3.74 to 6.9) · 3,569 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.79 (1.36 to 2.23) · 10,444 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.453, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.427, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.345, Oct 2024 – Sep 2025
See every measure and the patient survey for The Queens Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 3 better, 3 the same, 2 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.34 (1.12 to 1.55) | Worse | Jul 2022 – Jun 2024 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.47 (0.29 to 0.65) · 11,638 cases | Worse | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.32 (3.74 to 6.9) · 3,569 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.79 (1.36 to 2.23) · 10,444 cases | Worse | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.453 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.427 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.345 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0.12 to 1.78) · 2,583 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 181.61 (147.16 to 216.07) · 200 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.6 · 101 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 130 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.3 · 266 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 619 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.3 · 815 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 1,115 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 7,459 cases | None | Jul 2024 – Jun 2025 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.11 to 0.45) · 12,099 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.17 (0 to 2.44) · 1,411 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.9 (1.73 to 4.06) · 3,175 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.07 (2.95 to 11.2) · 1,400 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.22 (1.54 to 6.91) · 1,481 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.45 (0.06 to 2.83) · 821 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 163 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.751 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.143 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 501 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 1,438 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 10.8 · 272 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -5 · 698 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 15.4 · 799 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.4 · 1,657 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.6 (5.1 to 8.6) · 477 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.2 (9.1 to 13.9) · 477 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 171 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.4 · 122 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 17.5 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.6 (10 to 16.1) · 2,546 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 768 cases | No different | Jan 2024 – Dec 2024 |
What patients said (3,104 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 52% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$100,720
Medicare paid this office $100,720 for 445 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 320 | $48,827 | $93 |
| New patient visit (45+ min) | 89 | $11,268 | $127 |
| Short return visit (20+ min) | 83 | $7,424 | $66 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 254 | $4,775 | $13 |
| Diagnostic exam of bladder and urethra using an endoscope | 60 | $4,169 | $61 |
See all 9 services
| Return visit (30+ min) | 320 | $48,827 | $93 |
| New patient visit (45+ min) | 89 | $11,268 | $127 |
| Short return visit (20+ min) | 83 | $7,424 | $66 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 254 | $4,775 | $13 |
| Diagnostic exam of bladder and urethra using an endoscope | 60 | $4,169 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,330 | $102 |
| Ultrasound measurement of bladder capacity after voiding | 41 | $380 | $9 |
| Urinalysis, manual test | 92 | $335 | $3 |
| Ultrasound scan of pelvic region through rectum | 11 | $282 | $26 |
Procedures Medicare counted
| Prostate resection | 1-10 | None |
Who their Medicare patients are
445 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 15% · Women 18% · Also on Medicaid 9% · Health risk score 1.63. Above the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 75% · Chronic kidney disease 47% · Diabetes 43% · Coronary heart disease 33% · Cancer 29% · Atrial fibrillation 20% · Heart failure 17% · COPD 12% · Dementia 10% · Depression 9% · Stroke 7%.
The office billed $414,432, Medicare allowed $135,761 and paid $100,720; for 1,509 services of 49 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 445 | 1,509 | 75 | 1.63 | $414,432 | $100,720 |
| 2023 | 399 | 1,948 | 75 | 1.81 | $418,127 | $104,514 |
| 2022 | 328 | 2,083 | 75 | 1.62 | $287,706 | $98,039 |
| 2021 | 345 | 2,729 | 74 | 1.67 | $358,367 | $117,307 |
| 2020 | 133 | 854 | 73 | 1.92 | $122,596 | $38,547 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Return visit (30+ min) | 255 | $41,815 | $96 |
| Short return visit (20+ min) | 139 | $11,523 | $65 |
| New patient visit (45+ min) | 80 | $10,144 | $127 |
| Diagnostic exam of bladder and urethra using an endoscope | 51 | $3,634 | $60 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,564 | $104 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,483 | $62 |
| Insertion of stent in ureter using an endoscope | 11 | $1,437 | $120 |
| Biopsy of prostate gland | 11 | $1,125 | $102 |
| Ultrasound measurement of bladder capacity after voiding | 98 | $1,077 | $9 |
| Urinalysis, manual test | 197 | $1,051 | $3 |
| Ultrasound scan of pelvic region through rectum | 15 | $390 | $26 |
2022: 7 services
| Return visit (30+ min) | 163 | $28,543 | $103 |
| Short return visit (20+ min) | 184 | $17,859 | $71 |
| New patient visit (45+ min) | 63 | $7,729 | $123 |
| Diagnostic exam of bladder and urethra using an endoscope | 37 | $2,874 | $59 |
| Ultrasound measurement of bladder capacity after voiding | 113 | $1,261 | $9 |
| Urinalysis, manual test | 173 | $890 | $3 |
| Ultrasound scan of pelvic region through rectum | 11 | $297 | $27 |
2021: 11 services
| Return visit (30+ min) | 202 | $33,150 | $100 |
| Short return visit (20+ min) | 125 | $12,568 | $75 |
| New patient visit (45+ min) | 76 | $9,897 | $130 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 27 | $3,248 | $108 |
| Diagnostic exam of bladder and urethra using an endoscope | 38 | $2,926 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,252 | $59 |
| Insertion of stent in ureter using an endoscope | 13 | $1,813 | $139 |
| Ultrasound measurement of bladder capacity after voiding | 146 | $1,669 | $9 |
| Urinalysis, manual test | 180 | $896 | $3 |
| Review by radiologist of ureter or urethra image | 19 | $818 | $33 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | $786 | $52 |
2020: 6 services
| Return visit (30+ min) | 81 | $8,432 | $90 |
| New patient visit (45+ min) | 28 | $3,922 | $140 |
| Short return visit (20+ min) | 29 | $2,522 | $65 |
| Diagnostic exam of bladder and urethra using an endoscope | 18 | $1,195 | $66 |
| Ultrasound measurement of bladder capacity after voiding | 37 | $396 | $9 |
| Urinalysis, manual test | 54 | $226 | $3 |
Medicaid work
$2,534 in 2024
Medicaid paid $2,534 for 41 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 41 | $2,534 |
| 2024 | 41 | 1 | 14 | $2,534 |
| 2023 | 129 | 2 | 22 | $3,316 |
| 2022 | 177 | 3 | 19 | $0 |
| 2021 | 260 | 5 | 21 | $0 |
| 2020 | 47 | 1 | 18 | $0 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 78 | $3,242 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 51 | $74 |
2022
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 99 | $0 |
| Short return visit (20+ min) | 18 | $0 |
| Return visit (30+ min) | 60 | $0 |
2021
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 12 | $0 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 132 | $0 |
| Short return visit (20+ min) | 16 | $0 |
| Return visit (30+ min) | 64 | $0 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 36 | $0 |
2020
| Sales tax | 47 | $0 |
Drugs they prescribed that Part D paid
$716,038
Pharmacies billed $716,038 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (51 of 1,963) in 2024. Above the middle of the specialty; the typical urology clinician is at 2%.
1,619 generic and fewer than 11 brand-name prescriptions · $716,038 in drug cost · 73 antibiotic prescriptions to 58 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | 26 | $294,445 | $11,325 |
| Myrbetriq | 179 | $137,669 | $769 |
| Orgovyx | 34 | $91,728 | $2,698 |
| Gemtesa | 85 | $80,332 | $945 |
| Tamsulosin | 754 | $14,245 | $19 |
See all 18 drugs
| Xtandi | 26 | $294,445 | $11,325 |
| Myrbetriq | 179 | $137,669 | $769 |
| Orgovyx | 34 | $91,728 | $2,698 |
| Gemtesa | 85 | $80,332 | $945 |
| Tamsulosin | 754 | $14,245 | $19 |
| Finasteride | 394 | $7,573 | $19 |
| Potassium Citrate Er | 47 | $4,796 | $102 |
| Methenamine Hippurate | 36 | $3,808 | $106 |
| Testosterone | 15 | $2,745 | $183 |
| Oxybutynin Chloride Er | 78 | $2,092 | $27 |
| Dutasteride | 25 | $1,965 | $79 |
| Silodosin | 14 | $1,844 | $132 |
| Alfuzosin Hcl Er | 19 | $679 | $36 |
| Terazosin | 18 | $556 | $31 |
| Ciprofloxacin | 52 | $186 | $4 |
| Oxybutynin Chloride | 12 | $182 | $15 |
| Hydrocodone-Acetaminophen | 44 | $173 | $4 |
| Hydrochlorothiazide | 19 | $81 | $4 |
Year by year
| 2024 | 1,963 | 497 | 3% (51) | None | $716,038 |
| 2023 | 1,890 | 460 | 3% (57) | None | $1,089,993 |
| 2022 | 1,754 | 402 | 2% (41) | None | $931,526 |
| 2021 | 1,612 | 407 | 4% (61) | None | $387,589 |
| 2020 | 296 | 150 | 11% (33) | None | $29,394 |
| 2019 | 21 | 19 | 81% (17) | None | $72 |
| 2018 | 69 | 63 | 96% (66) | 0% | $408 |
| 2017 | 68 | 57 | 82% (56) | None | $771 |
| 2016 | 52 | 42 | 79% (41) | None | $701 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 18 drugs
| Xtandi | 45 | $618,696 | $13,749 |
| Myrbetriq | 256 | $218,761 | $855 |
| Orgovyx | 17 | $43,480 | $2,558 |
| Gemtesa | 32 | $29,744 | $929 |
| Tamsulosin | 672 | $13,408 | $20 |
| Potassium Citrate Er | 56 | $9,524 | $170 |
| Finasteride | 349 | $5,973 | $17 |
| Oxybutynin Chloride Er | 121 | $3,909 | $32 |
| Testosterone | 11 | $2,859 | $260 |
| Trospium Chloride | 12 | $2,196 | $183 |
| Methenamine Hippurate | 12 | $1,166 | $97 |
| Bethanechol Chloride | 19 | $970 | $51 |
| Alfuzosin Hcl Er | 21 | $574 | $27 |
| Terazosin | 11 | $244 | $22 |
| Hydrocodone-Acetaminophen | 39 | $197 | $5 |
| Ciprofloxacin | 41 | $145 | $4 |
| Hydrochlorothiazide | 17 | $74 | $4 |
| Oxycodone | 13 | $42 | $3 |
2022: 11 drugs
| Xtandi | 40 | $495,962 | $12,399 |
| Myrbetriq | 306 | $211,414 | $691 |
| Orgovyx | 17 | $41,039 | $2,414 |
| Tamsulosin | 567 | $11,180 | $20 |
| Potassium Citrate Er | 77 | $10,379 | $135 |
| Gemtesa | 14 | $8,934 | $638 |
| Oxybutynin Chloride Er | 134 | $6,264 | $47 |
| Finasteride | 356 | $5,911 | $17 |
| Bethanechol Chloride | 20 | $2,483 | $124 |
| Ciprofloxacin | 52 | $176 | $3 |
| Hydrocodone-Acetaminophen | 35 | $150 | $4 |
2021: 16 drugs
| Xtandi | 17 | $206,158 | $12,127 |
| Myrbetriq | 177 | $121,140 | $684 |
| Oxybutynin Chloride Er | 196 | $9,097 | $46 |
| Tamsulosin | 526 | $7,382 | $14 |
| Testosterone | 11 | $6,803 | $618 |
| Finasteride | 377 | $6,184 | $16 |
| Potassium Citrate Er | 26 | $3,688 | $142 |
| Trospium Chloride Er | 15 | $2,360 | $157 |
| Bethanechol Chloride | 24 | $1,540 | $64 |
| Silodosin | 12 | $1,505 | $125 |
| Oxybutynin Chloride | 13 | $274 | $21 |
| Hydrocodone-Acetaminophen | 43 | $173 | $4 |
| Ciprofloxacin | 49 | $126 | $3 |
| Nitrofurantoin Mono-Macro | 11 | $101 | $9 |
| Sulfamethoxazole-Trimethoprim | 13 | $31 | $2 |
| Oxycodone | 11 | $27 | $2 |
2020: 8 drugs
| Myrbetriq | 32 | $19,165 | $599 |
| Oxybutynin Chloride Er | 33 | $1,396 | $42 |
| Finasteride | 63 | $987 | $16 |
| Tamsulosin | 62 | $903 | $15 |
| Oxycodone | 16 | $92 | $6 |
| Hydrocodone-Acetaminophen | 13 | $38 | $3 |
| Ciprofloxacin | 14 | $34 | $2 |
| Sulfamethoxazole-Trimethoprim | 14 | $30 | $2 |
2018: 3 drugs
| Hydrocodone-Acetaminophen | 19 | $126 | $7 |
| Tramadol | 35 | $109 | $3 |
| Oxycodone | 12 | $75 | $6 |
2017: 2 drugs
| Hydrocodone-Acetaminophen | 41 | $336 | $8 |
| Oxycodone | 12 | $105 | $9 |
2016: 1 drug
| Hydrocodone-Acetaminophen | 33 | $407 | $12 |
Money from drug and device companies
$1,208 in 2025
| 2025 | 9 | 42 | None | $1,208 |
| 2024 | 12 | 58 | $125 | $2,605 |
| 2023 | 10 | 41 | None | $1,296 |
| 2022 | 11 | 61 | None | $1,391 |
| 2021 | 10 | 27 | None | $716 |
| 2020 | 6 | 8 | None | $172 |
| 2019 | 3 | 15 | None | $1,471 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Astellas Pharma US | Xtandi | $327 | 8 payments
|
| Pfizer | Xtandi | $287 | 13 payments
|
| Janssen Biotech | Erleada | $230 | 6 payments
|
| Sumitomo Pharma America | Orgovyx | $158 | 8 payments
|
| Immunitybio | Anktiva | $66 | 3 payments
|
| Abbott Laboratories | Cardiomems | $56 | 1 payment
|
See all 42 published payments
| Pfizer | Meals · 2025-12-16 | Xtandi | $17 |
| Pfizer | Meals · 2025-12-16 | Xtandi | $3 |
| Astellas Pharma US | Meals · 2025-12-09 | Xtandi | $20 |
| Sumitomo Pharma America | Meals · 2025-12-02 | Orgovyx | $26 |
| Sumitomo Pharma America | Meals · 2025-11-19 | Orgovyx | $9 |
| Sumitomo Pharma America | Meals · 2025-11-19 | Orgovyx | $14 |
| Pfizer | Meals · 2025-11-19 | Xtandi | $26 |
| Urogen Pharma | Meals · 2025-11-11 | Zusduri | $22 |
| Janssen Biotech | Meals · 2025-11-05 | Erleada | $34 |
| Pfizer | Meals · 2025-11-04 | Xtandi | $17 |
| Pfizer | Meals · 2025-10-30 | Xtandi | $25 |
| Pfizer | Education · 2025-10-29 | Orgovyx | $10 |
| Astellas Pharma US | Meals · 2025-10-28 | Xtandi | $25 |
| Janssen Biotech | Meals · 2025-10-14 | Erleada | $37 |
| Pfizer | Meals · 2025-09-24 | Xtandi | $1 |
| Pfizer | Meals · 2025-09-23 | Xtandi | $26 |
| Sumitomo Pharma America | Meals · 2025-09-22 | Orgovyx | $26 |
| Astellas Pharma US | Education · 2025-09-03 | None | $99 |
| Astellas Pharma US | Education · 2025-09-03 | None | $89 |
| Astellas Pharma US | Meals · 2025-08-27 | Xtandi | $18 |
| Immunitybio | Meals · 2025-08-26 | Anktiva | $18 |
| Boston Scientific | Meals · 2025-07-24 | General - Kidney Stone Disease | $37 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-07-23 | Nubeqa | $25 |
| Astellas Pharma US | Meals · 2025-07-15 | Xtandi | $25 |
| Janssen Biotech | Meals · 2025-07-09 | Erleada | $31 |
| Janssen Biotech | Education · 2025-06-18 | Erleada | $68 |
| Immunitybio | Meals · 2025-06-10 | Anktiva | $25 |
| Pfizer | Meals · 2025-05-28 | Xtandi | $23 |
| Pfizer | Meals · 2025-05-28 | Xtandi | $2 |
| Abbott Laboratories | Meals · 2025-05-19 | Cardiomems | $56 |
| Sumitomo Pharma America | Meals · 2025-05-12 | Gemtesa | $20 |
| Astellas Pharma US | Meals · 2025-05-06 | Xtandi | $28 |
| Sumitomo Pharma America | Meals · 2025-04-30 | Orgovyx | $22 |
| Janssen Biotech | Meals · 2025-04-15 | Erleada | $32 |
| Sumitomo Pharma America | Meals · 2025-03-27 | Orgovyx | $23 |
| Immunitybio | Meals · 2025-03-12 | Anktiva | $24 |
| Astellas Pharma US | Meals · 2025-03-04 | Xtandi | $22 |
| Pfizer | Meals · 2025-02-26 | Xtandi | $2 |
| Pfizer | Meals · 2025-02-26 | Xtandi | $20 |
| Janssen Biotech | Meals · 2025-02-25 | Erleada | $28 |
| Pfizer | Meals · 2025-02-05 | Xtandi | $114 |
| Sumitomo Pharma America | Meals · 2025-01-28 | Orgovyx | $20 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,605
| Edap Technomed | None | $687 | 3 payments
|
| Astellas Pharma US | Xtandi | $424 | 10 payments
|
| Boston Scientific | Lithovue | $326 | 4 payments
|
| Sumitomo Pharma America | Orgovyx | $322 | 12 payments
|
| Abbott Laboratories | Diamondback Peripheral | $279 | 3 payments
|
| Pfizer | Xtandi | $273 | 14 payments
|
| Janssen Biotech | Erleada | $136 | 5 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $63 | 3 payments
|
| Janssen Scientific Affairs | Erleada | $37 | 1 payment
|
| Endo USA | Xiaflex | $22 | 1 payment
|
| Urogen Pharma | Jelmyto | $20 | 1 payment
|
| Endo Pharmaceuticals | Xiaflex | $15 | 1 payment
|
2023: $1,296
| Sumitomo Pharma America | Orgovyx | $353 | 7 payments
|
| Pfizer | Xtandi | $197 | 14 payments
|
| Janssen Biotech | Erleada | $191 | 6 payments
|
| Teleflex | Urolift | $146 | 3 payments
|
| Endo Pharmaceuticals | Xiaflex | $122 | 1 payment
|
| Edap Technomed | None | $85 | 1 payment
|
| Astellas Pharma US | Myrbetriq | $77 | 3 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $75 | 3 payments
|
| C. R. Bard Inc. & Subsidiaries | Bard Urinary Drainage Bag | $36 | 2 payments
|
| Boston Scientific | Spaceoar System | $15 | 1 payment
|
2022: $1,391
| Pfizer | Xtandi | $410 | 22 payments
|
| Astellas Pharma US | Xtandi | $407 | 14 payments
|
| Janssen Biotech | Erleada | $199 | 7 payments
|
| Myovant Sciences | Orgovyx | $139 | 7 payments
|
| Boston Scientific | Spaceoar Vue System - 10ml | $46 | 2 payments
|
| Abbvie | Lupron Depot | $45 | 2 payments
|
| Ethicon US | Surgicel Nu-Knit | $42 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $40 | 2 payments
|
| PROCEPT BioRobotics | Aquabeam Robotic System | $25 | 1 payment
|
| Endo Pharmaceuticals | Xiaflex | $24 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $14 | 1 payment
|
2021: $716
| Astellas Pharma US | Xtandi | $356 | 11 payments
|
| Myovant Sciences | Orgovyx | $73 | 4 payments
|
| KARL STORZ Endoscopy-America | N.A. | $63 | 1 payment
|
| AbbVie | Lupron Depot | $49 | 3 payments
|
| Boston Scientific | Rezum | $41 | 2 payments
|
| Pfizer | Xtandi | $40 | 2 payments
|
| TOLMAR Pharmaceuticals | Eligard | $32 | 1 payment
|
| Endo Pharmaceuticals | Xiaflex | $23 | 1 payment
|
| Smith+Nephew | Stravix | $22 | 1 payment
|
| Teleflex | Urolift System | $18 | 1 payment
|
2020: $172
| Astellas Pharma US | Xtandi | $56 | 3 payments
|
| Biotronik | None | $28 | 1 payment
|
| Boston Scientific | Lithovue Empower | $27 | 1 payment
|
| Janssen Biotech | Erleada | $26 | 1 payment
|
| Smith+Nephew | Stravix | $18 | 1 payment
|
| NeoTract | Urolift | $15 | 1 payment
|
2019: $1,471
| Boston Scientific | Ams | $1,209 | 13 payments
|
| Medtronic USA | Interstim | $141 | 1 payment
|
| Antares Pharma | Otrexup | $121 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 94.2 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1043630726
- Licence
- CA A137673California A137673: Current · expires 2026-10-31
- Group
- Aloha Urology Inc
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X); Student in a training program (390200000X)
- Mailing address
- 1329 Lusitana St Ste 406, Honolulu, HI, 96813
- NPI first listed
- 2014-04-22
- NPI last updated
- 2020-08-03
- NPI record certified
- 2020-08-03
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Drive, Stanford, CA, 94305